) or 4 antiretroviral drugs plus hydroxyurea and interleukin-2 ( ) for 24 n p 15 n p 15 months, followed by 1-3 structured therapeutic interruptions (STIs). Viral control, defined as maintaining plasma viremia !5000 copies/mL without therapy, was achieved in 14 cases. Lymphocyte subsets, plasma HIV-1 RNA loads, proviral DNA loads in peripheral blood mononuclear cells (PBMCs), residual HIV-1 RNA loads in PBMCs and in lymph node cells, and anti-p24 lymphoproliferative response were measured. In the multivariate analysis, proviral DNA loads in PBMCs and anti-p24 lymphoproliferative response assessed at 24 months were independently correlated with viral control after STI. These results enabled us to define a subgroup of patients for whom safe discontinuation of therapy initiated at acute infection was suitable and contributed to ascertaining priority for biological parameter assessment in future clinical trials.
Thirty patients with acute human immunodeficiency virus (HIV) type 1 infection received a combination of 3 antiretroviral drugs (
) or 4 antiretroviral drugs plus hydroxyurea and interleukin-2 ( ) for 24 n p 15 n p 15 months, followed by 1-3 structured therapeutic interruptions (STIs). Viral control, defined as maintaining plasma viremia !5000 copies/mL without therapy, was achieved in 14 cases. Lymphocyte subsets, plasma HIV-1 RNA loads, proviral DNA loads in peripheral blood mononuclear cells (PBMCs), residual HIV-1 RNA loads in PBMCs and in lymph node cells, and anti-p24 lymphoproliferative response were measured. In the multivariate analysis, proviral DNA loads in PBMCs and anti-p24 lymphoproliferative response assessed at 24 months were independently correlated with viral control after STI. These results enabled us to define a subgroup of patients for whom safe discontinuation of therapy initiated at acute infection was suitable and contributed to ascertaining priority for biological parameter assessment in future clinical trials.
Pathophysiological events occurring at primary human immunodeficiency virus (HIV) type 1 infection (PHI) determine the subsequent course of HIV disease [1] . Treatment with highly active antiretroviral therapy (HAART) initiated at this stage leads to sustained suppression of plasma virus load in conjunction with immune system recovery [2, 3] . However, the premature occurrence of dyslipidemia and lipodystrophy in some post-PHI-treated patients has led to uncertainties as to the long-term benefit of such strategies [4] [5] [6] . Although international guidelines still recommend treating PHI [7] , an increasing number of physicians are now adopt-ing a more conservative approach and delay initiation of HAART, despite demonstrations by several studies that HIV-specific CD4 T cells can only be preserved when therapy is initiated at PHI [8, 9] . HAART discontinuation after several months, or short-course therapy, could therefore constitute a valid approach for limiting the long-term effects of therapy while enhancing immune control of viral replication [10, 11] . The use of structured therapeutic interruptions (STIs) also has been underlined as a technique for improving viral control after ceasing therapy [12, 13] . However, because effective control is generally obtained in less than half of cases [14] , it may be useful to determine the prognostic factors correlated with control, to pinpoint which patients could benefit from this strategy. We analyzed this issue in a cohort of patients treated after PHI.
PATIENTS AND METHODS

Population.
Between January 1998 and April 2002, we invited patients who had received a diagnosis of PHI to take part in 2 pilot studies. The first trial used triple nucleoside analogue reverse-transcriptase inhibitor (NRTI) therapy, including zidovudine (300 mg twice daily), lamivudine (150 mg twice daily), and didanosine (400 mg once daily) for 24 months, followed by 3 STI cycles. The second trial used a combination of 2 NRTIs (stavudine [40 mg twice daily] plus didanosine [400 mg once daily]) combined with 2 protease inhibitors (PIs; nelfinavir [1250 mg twice daily] and saquinavir soft-gel capsule [1200 mg twice daily]) for 24 months. Hydroxyurea (HU; 500 mg twice daily) was added from month 3 to month 24 to target the latent viral reservoir, and 2 courses of interleukin (IL)-2 were also administered subcutaneously (3 MIU twice daily for 6 consecutive days) between months 15 and 18. The introduction of HU differed to month 3 in the protocol, to avoid blunting the CD4 cell recovery with HAART after the peak of viremia. The administration of IL-2 was chosen at a time when plasma viremia had been controlled for several months. Three STI cycles were also performed at 24 months.
STI setup was identical in both trials: all drugs were stopped at month 24, and plasma HIV-1 RNA was measured weekly for the first 4 weeks and then every 2 weeks. Antiretroviral drugs were resumed when plasma HIV-1 RNA was found to be 150,000 copies/mL at least once or 15000 copies/mL on 2 occasions at a 2-week interval. The next STI cycle was initiated when plasma HIV-1 RNA had returned to !20 copies/mL for 2 months.
The present study was approved by the local ethics committee, and patients gave their written informed consent before entering the study. Responders were defined as having maintained plasma viremia !5000 copies/mL at least 6 months after an STI and until the last evaluation available for study.
Participants were offered access to either trial and could also choose to be excluded from clinical trials. Between 1998 and 2002, 35 patients were included in the first therapy group, and 19 patients were included in the second therapy group. However, only 45 patients (27 in the first group and 18 in the second) completed the 24 months of therapy because 9 patients were lost to follow-up. Subsequently, 15 patients did not participate to the STI part of the study because they had detectable viremia at the end of therapy (12 patients in the first group and 3 patients in the second group), because they had compliance problems (11 patients), or because they had viral resistance (4 patients). Thirty patients (15 in each therapy group) fulfilled the selection criteria for analysis: trial completion (HAART and STIs), plasma HIV-1 RNA !20 copies/mL at month 24, and cryopreserved blood lymphocytes at the time of PHI diagnosis and at month 24.
PHI diagnosis. Patients who were thought to have PHI underwent serological tests by ELISA (Axsym HIV-1/2; Abbott Diagnostics) and Western-blot analysis (HIV Blot 2.2; Genelabs Diagnostics). In addition, plasma HIV-1 RNA was measured immediately, and the results were obtained within 2 days. All included patients had symptomatic PHI with р3 bands on Western-blot analysis.
HIV-1 RNA loads. Plasma HIV-1 RNA loads were measured by use of the HIV Monitor kit (limit of detection, 20 copies/mL; Roche Diagnostics) [15] . At 24 months, patients underwent a surgical lymph node biopsy, performed under local anesthesia, to evaluate HIV-1 RNA loads in lymph node mononuclear cells (LNMCs), as described elsewhere [16] . Furthermore, HIV-1 RNA loads were also measured in PBMCs before HAART was stopped at 24 months, as described elsewhere [17] . The lower limit of detection in both LNMCs and PBMCs was 20 HIV-1 RNA copies/10 6 cells. Proviral HIV-1 DNA loads. PBMCs were isolated by a Ficoll gradient (MSL; EUROBIO) and stored at Ϫ80ЊC. Extraction for HIV-1 DNA quantification was performed with the Whole Blood Specimen Preparation Kit (Roche Diagnostics). After extraction from an input of 1-3 million cells, HIV-1 DNA was quantified by use of an adapted version of the Amplicor HIV-1 Monitor 1.5 test, incorporating an internal quantitative standard (courtesy of Roche Diagnostics), plus the standard commercial kit, as reported elsewhere [18, 19] .
Resistance testing. Plasma HIV-1 RNA extracted from clinical samples after 24 months of HAART was analyzed for reverse-transcriptase and protease gene sequencing by use of the TruGene kit (Visible Genetics).
Lymphocyte subsets. Lymphocyte subsets were determined by flow cytometry on freshly isolated cells (EPICS Profile; Coulter) and commercially available monoclonal antibodies against CD3, CD4, CD8, CD38 (Coulter), CD45RO, CD45RA, and HLA-DR (Dako).
Lymphoproliferation assay. PBMCs were resuspended at a concentration of 10 6 cells/mL in RPMI medium (EUROBIO) with 10% human AB serum, and cells in 200 mL were 5 2 ϫ 10 placed in 96-well round-bottomed plates. Recombinant HIV-1 p24 antigen (Protein Sciences) was used at a concentration of 1 mg/mL. Cells were incubated with p24 for 6 days, then pulsed with 1 mCi of [ 3 H]thymidine/well (Amersham) for 12-18 h before harvesting. Radioactivity was measured by a beta counter (Packard). The stimulation index (SI) for p24 antigen was determined by dividing counts per minute obtained from PBMCs stimulated with p24 by counts per minute obtained from PBMCs stimulated with control protein. On the basis of the results obtained from uninfected blood donors, an SI 13 was considered to be a positive response.
Statistical analysis. Patients with undetectable virus loads (!20 HIV copies/mL) were arbitrarily considered as having 19 copies/mL. Virus load results were log-transformed for analytical purposes. The Mann-Whitney U test was used to compare continuous variables between patient groups, and the Fisher's exact test was used to compare categorical variables between patient groups (i.e., therapy type, responders, and nonresponders). A discriminant analysis was performed to determine variables capable of identifying patients with a higher posttherapy control probability. The selected variables were those with a significance of !.20 in the univariate analysis. Logistic regression was also used to calculate the relative response risks for each variable entered in the model. Cox proportional-hazard modeling was performed in the population of 30 patients, to identify parameters correlated with time to viral control. The time variable was considered as the time required to be classified as responder after stopping therapy for the first time at 24 months. Patients without viral control were censored after 24 weeks of observation after the third STI. Kaplan-Meier estimates were performed, and the log-rank test was used to compare patients with a positive or negative lymphoproliferative response at 24 months, and those with higher or lower proviral DNA loads in PBMC versus the population median at 24 months. NCSS software (Statistical Systems) was used for statistical analysis.
RESULTS
Population.
Fifteen patients did not fulfill the inclusion criteria after 24 months of HAART because of detectable plasma viremia; in addition, 11 patients had compliance problems, and 4 showed evidence of drug resistance. The first 11 patients presented a wild-type HIV-1 strain on plasma HIV-1 RNA sequenced at 24 months and reached undetectable levels after the same HAART regimen was resumed. Three patients in the first therapy group and 1 patient in the second group had resistance mutations, as assessed by plasma viremia sequenced after completion of 24 months of therapy; nucleoside analogue mutations were detected in all cases (codons 41, 215, and 219) plus a D30N and a L90M mutation in 1 patient. These patients were subsequently switched to other regimens guided by genotype testing and reached undetectable viremia. No STI was performed for these 15 patients during the observation period.
The final study included 30 patients, including 19 men and 11 women, with a median age of 33.5 years (range, 19-52 years). For 27 patients, HIV-1 infection was acquired by sexual contact (homosexual for 14 and heterosexual for 13); for 3 patients, infection was acquired by intravenous drug use. The population baseline characteristics are shown in table 1. Fifteen patients received triple-NRTI therapy, and 15 were administered a combination of 2 NRTIs plus 2 PIs plus HU and IL-2. At baseline, no statistically significant differences were found between the 2 therapy groups in terms of age, plasma HIV-1 RNA loads, and lymphocyte subsets (Mann-Whitney U test).
Evolution of plasma viremia. After initiation of therapy, plasma HIV-1 RNA loads decreased to !20 copies/mL in all patients and remained stable over the next few months. The entire cohort therefore had undetectable virus loads at 24 months, when therapy was interrupted for the first time. Overall, viral control was obtained after 1-3 STIs, for 14 patients, but the other 16 patients needed to resume HAART after the third STI. Viral control was obtained after the first STI in 4 patients, including 2 patients whose virus loads remained permanently at !20 copies/mL (follow-up, 24 and 12 months), after the second STI in 6 patients and the third STI in 4 patients. The median follow-up of these 14 responders is 14 months, and no patient experienced an increase in viremia to 15000 copies/mL during this period. Most patients experienced a viremia peak after each STI, then decreased to a new steady state over the ensuing 2-3 weeks.
Evolution of CD4 cell count. A median increase of +362 CD4 cells/mL was observed in the 30 patients after 24 months of therapy (triple-NRTI group, median increase of 202 cells/ mL; immune-based therapy group, median increase of 492 cells/ mL). At the end of the last STI performed for each patient, a median decrease of Ϫ102 CD4 cells/mL was found in the series as a whole, compared with month 24. When the 14 responders only are considered, this median decrease was Ϫ18 cells/mL after a median period of observation of 14 months.
Adverse events. During the 24-month period of therapy, no grade 3/4 biological abnormality was observed in the triple-NRTI group. In the group receiving HU, 3 patients experienced a decrease in leukocyte counts, necessitating a temporal reduction of the HU dosage (500 mg every other day). Furthermore, 4 patients in this group experienced lipoatrophy that remained stable during the STI period, and 1 patient experienced peripheral neuritis. No patient experienced lactic acidosis during the study period.
Univariate analysis. Aside from demographic data, the following parameters were available for each patient: CD4 + and CD8 + cell counts at the time of PHI diagnosis (defined as baseline) and at 24 months, CD4 + CD45R0 + cell counts at baseline and at 24 months, CD4 + CD45RA + cell counts at baseline and at 24 months, plasma HIV-1 RNA loads at baseline, CD8 + CD38 + cell counts at 24 months, CD3 + HLA-DR + cell counts at 24 months, proviral DNA loads in PBMCs at baseline and at 24 months, residual HIV-1 RNA loads in PBMCs and in LNMCs at 24 months, and the results of the lymphoproliferation assay performed at 24 months. Responders were characterized by lower PBMC HIV-1 RNA and DNA loads and higher anti-p24 SIs at 24 months, after receiving a quadrupledrug combination plus HU and IL-2 (table 2) .
Multivariate and time-series analyses. The discriminant analysis identified proviral DNA loads in PBMCs and anti-p24 SI at 24 months as independent predictors of response; we were able to classify 90% of our observations efficiently by using these 2 measurements in the model. A nominal logistic regression analysis that included these 2 variables recorded as less than or greater than median proviral DNA load and !3 or у3 anti-p24 SI at 24 months was also performed. Proviral DNA load and anti-p24 SI at 24 months were confirmed as independent predictors of response, with odds ratios of 0.08 (95% confidence interval [CI], 0.003-0.660) and 28.78 (95% CI, 3.56-648.43), respectively. We subsequently conducted a timeseries analysis, to test the potential influence of the various parameters measured at baseline and at 24 months on the time to plasma viremia control after therapy ceased. Once again, the Cox proportional-hazard model identified proviral DNA loads and anti-p24 SI as factors correlated with time to response, with hazard ratios of 0.097 (95% CI, 0.016-0.602) and 6.97 (95% CI, 1.32-36.68), respectively. Figure 1 shows the probability of response according to proviral DNA loads or the lymphoproliferative index.
DISCUSSION
Two patient groups that underwent different therapeutic strategies at PHI were selected for 3 STI cycles after 24 months of therapy. These groups were comparable at the time of diagnosis in terms of demographics and biological parameters, and the groups included patients with extensive evaluations of virus load and lymphocyte subsets, along with anti-HIV-1 immune response measurements. We then analyzed viral control predictors after up to 3 STIs, on the basis of maintaining plasma HIV-1 RNA loads !5000 copies/mL in the absence of therapy, as in other trials [20] . Although responders and nonresponders differed in terms of several assessed parameters, factors independently correlated with response were a low level of proviral DNA in PBMCs at completion of therapy and a positive proliferative response against p24.
Recently published studies of both animals and humans suggest that the virological set point can be altered by early therapeutic intervention during PHI [12, [20] [21] [22] . Although this effect was not proven in an additional trial of 16 subjects [23] , the patients in question had early-infected cases, rather than true cases, of acute infection. Certain trials testing the efficacy of immune interventions to increase specific anti-HIV-1 immune response, such as IL-2, have failed to demonstrate any significant benefits [24] . The addition of IL-2 to HAART has also been tested during chronic HIV-1 infection, to decrease the residual viral pool [25] . We used this approach in our second group of patients, along with the HU combination, to decrease the pool of latently infected cells [26] . The first group of patients received a fairly classic triple-NRTI combination, a regimen that had been previously proven capable of driving plasma viremia to undetectable levels [27] but usually is considered to be less effective than a PI-based regimen [28] , particularly on lymphoid reservoirs [29] . Overall, sustained viremia control of !5000 HIV copies/mL was obtained after 1-3 STI cycles in 46.6% of patients in our series, with all patients having initiated treatment at the time of seroconversion. However, therapy content at PHI was not an independent predictor of subsequent viral control in the multivariate analysis, although receiving the quadruple-drug regimen plus HU and IL-2 was more frequently associated with response in the univariate analysis. In fact, reaching low PBMC proviral DNA loads proved to be the main independent viral parameter predictive of response. Perhaps the use of HU widened the number and type of cells targeted by therapy and decreased viral reservoirs more effectively, as observed during the later stages of HIV-1 infection [30] . This mechanism is probably as important as HU's cytostatic effect on activated lymphocytes, as observed by Garcia et al. [26] , because, in the present study, in contrast to that of Garcia et al., HU was discontinued during STI. The quadruple-drug combination including 2 PIs may also have been a kind of intensified HAART regimen on covert viral replication [31] .
The prognostic value of PBMC proviral DNA loads was recently demonstrated during chronic HIV-1 infection [32] and proved to be independent of plasma HIV-1 RNA loads. Although therapy duration was arbitrarily fixed at 24 months for all patients in the present study, it may be possible to anticipate different conclusions by using different treatment periods. Previous trials have shown that the decay rates of PBMC proviral DNA loads are very slow during treatment of acute HIV-1 infection [33, 34] and that reaching low loads is clearly a timedependent factor. Furthermore, viral reservoirs are known to be formed early after infection [35] and tend to remain constant during the course of untreated HIV-1 disease [36, 37] .
The presence of a low residual provirus load was reinforced Kaplan-Meier curves on the probability of response, according to proviral DNA loads less than or more than median value at 24 months or the anti-p24 stimulation index (SI) measured at 24 months of highly active antiretroviral therapy (HAART). Time to the first stable human immunodeficiency virus (HIV) load value !5000 copies/mL was used for responders. Time 0 represents the end of the 24 months of continued HAART and the time of the first structured therapeutic interruption.
by the presence of a specific lymphoproliferative response against p24, and 89% of patients possessing these 2 favorable parameters at 24 months achieved viral control. It should be noted that the measurement of HIV-1-specific immunity used in this study is limited; it is now known that immune response to other HIV-1 antigens is an important factor, and the measurement of specific IFN-g-producing cells has currently supplanted lymphoproliferation assays. However, both of these approaches have shown flaws, which may be due to a defect in CD4-specific cell proliferation [38] . Finally, with regard to the present study, we cannot determine whether specific proliferation was restored or protected by HAART because of a lack of assessment before month 24.
Taken together, these data argue for early interventions capable of decreasing HIV-1 cellular reservoirs as much as possible at a time when the immune system is less damaged. The quantitative evaluation of lymphocyte subsets was not predictive of response. Lymphocyte activation markers were low in most patients as a result of the sustained undetectability of plasma viremia with HAART. The fact that residual levels of cell-associated HIV-1 RNA were not predictive of response in either blood or lymph node tissues is also noteworthy. However, given the small sample size of our trial, the power could have been insufficient to detect lack of association, and further studies are necessary to determine whether other markers could be useful for determining patient evolution after therapy ceased.
In our opinion, these data can contribute to treatment of acute HIV-1-infected patients. At a time when long-term HAART is thwarted by drug-induced side effects and compliance problems, the efficient determination of patient subgroups able to safely interrupt therapy is of utmost importance. Future clinical trials should focus on strategies for reducing proviral reservoirs as much and as quickly as possible while maintaining or reinforcing an HIV-1-specific immune response.
